EP Patent

EP1076066A1 — Peptides for lowering blood glucose levels

Assigned to Zealand Pharma AS · Expires 2001-02-14 · 25y expired

What this patent protects

The present invention relates to novel variants that lower blood glucose levels, specific variants of exendin-4. The invention further relates to peptide conjugates that lower blood glucose levels and which have increased bioavailability.

USPTO Abstract

The present invention relates to novel variants that lower blood glucose levels, specific variants of exendin-4. The invention further relates to peptide conjugates that lower blood glucose levels and which have increased bioavailability.

Drugs covered by this patent

Patent Metadata

Patent number
EP1076066A1
Jurisdiction
EP
Classification
—
Expires
2001-02-14
Drug substance claim
No
Drug product claim
No
Assignee
Zealand Pharma AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.